- Home
- OPFI vs LUNG Comparison
OPFI vs LUNG Comparison
Compare OPFI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- LUNG
- Stock Information
- Founded
- OPFI 2009
- LUNG 1995
- Country
- OPFI United States
- LUNG United States
- Employees
- OPFI N/A
- LUNG N/A
- Industry
- OPFI Finance: Consumer Services
- LUNG Industrial Specialties
- Sector
- OPFI Finance
- LUNG Health Care
- Exchange
- OPFI Nasdaq
- LUNG Nasdaq
- Market Cap
- OPFI 336.3M
- LUNG 124.0M
- IPO Year
- OPFI N/A
- LUNG 2020
- Fundamental
- Price
- OPFI $13.57
- LUNG $2.72
- Analyst Decision
- OPFI Buy
- LUNG Buy
- Analyst Count
- OPFI 2
- LUNG 6
- Target Price
- OPFI $11.75
- LUNG $11.53
- AVG Volume (30 Days)
- OPFI 1.4M
- LUNG 324.6K
- Earning Date
- OPFI 08-06-2025
- LUNG 07-30-2025
- Dividend Yield
- OPFI 7.41%
- LUNG N/A
- EPS Growth
- OPFI N/A
- LUNG N/A
- EPS
- OPFI N/A
- LUNG N/A
- Revenue
- OPFI $305,566,000.00
- LUNG $87,473,000.00
- Revenue This Year
- OPFI $112.80
- LUNG $18.02
- Revenue Next Year
- OPFI $9.34
- LUNG $18.17
- P/E Ratio
- OPFI N/A
- LUNG N/A
- Revenue Growth
- OPFI 31.46
- LUNG 19.84
- 52 Week Low
- OPFI $3.09
- LUNG $2.50
- 52 Week High
- OPFI $17.73
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- OPFI 54.53
- LUNG 32.78
- Support Level
- OPFI $12.38
- LUNG $2.52
- Resistance Level
- OPFI $15.03
- LUNG $2.67
- Average True Range (ATR)
- OPFI 0.77
- LUNG 0.15
- MACD
- OPFI -0.00
- LUNG 0.01
- Stochastic Oscillator
- OPFI 57.43
- LUNG 6.93
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.